ЛОСАРДЭКС 50

Nazione: Israele

Lingua: russo

Fonte: Ministry of Health

Compra

Principio attivo:

LOSARTAN POTASSIUM 50 MG

Commercializzato da:

DEXCEL PHARMA TECHNOLOGIES LTD

Codice ATC:

C09CA01

Forma farmaceutica:

TABLETS

Via di somministrazione:

PER OS

Prodotto da:

DEXCEL LTD

Gruppo terapeutico:

LOSARTAN

Indicazioni terapeutiche:

Hypertension: Losardex is indicated for the treatment of hypertension. Heart failure: Losardex is indicated for the treatment of heart failure (NYHA II and III) usually in addition to diuretics and/or digitalis if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

Data dell'autorizzazione:

2013-03-01

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo inglese 14-06-2020
Scheda tecnica Scheda tecnica inglese 27-02-2023
Foglio illustrativo Foglio illustrativo arabo 06-09-2023
Foglio illustrativo Foglio illustrativo ebraico 14-06-2020

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti